Removal of Haemangiomas, Rosacea & Acne — Cost, Top Hospitals & Success Rates | MyMedicPlus

This guide covers dermatological procedures for three clinically distinct but commonly co-addressed skin conditions: infantile haemangiomas, rosacea (including telangiectasia and rhinophyma), and acne removal. While unrelated in pathophysiology, these conditions share the therapeutic goal of reducing visible skin lesions — vascular, inflammatory, or comedonal — through a combination of pharmacological, laser, and procedural approaches.

Infantile Haemangiomas (IH) are the most common benign vascular tumours of infancy, affecting approximately 5–10% of Caucasian infants. They proliferate rapidly in the first 6–9 months of life before involuting over 3–7 years, often leaving residual fibrofatty tissue or surface telangiectasia. High-risk IH — those involving the airway, periorbital region, liver, or causing ulceration and significant disfigurement — require active treatment. Since the landmark IPHES randomised controlled trial (Léauté-Labrèze 2015, N Engl J Med), oral propranolol (HEMANGIOL) has replaced surgery and systemic corticosteroids as the first-line standard of care, demonstrating >96% complete or near-complete response at 24 weeks with 3 mg/kg/day.

Rosacea is a chronic inflammatory facial dermatosis affecting approximately 5% of adults globally, characterised by central facial erythema, telangiectasia, inflammatory papules and pustules (classified as subtypes I–IV by the National Rosacea Society), and in advanced cases, rhinophyma — sebaceous gland hypertrophy of the nose. Treatment is multimodal: topical agents address the papulopustular component, vascular lasers target telangiectasia, and CO2 laser reshapes rhinophymatous change.

Acne removal procedures refer to office-based dermatological interventions — including comedone extraction, intralesional corticosteroid injections for nodules, chemical peels, and phototherapy — used alongside or as adjuncts to systemic acne pharmacotherapy. These targeted procedures address specific lesion types and complement topical and oral regimens in patients with resistant or severe acne.

• Infantile haemangioma — high-risk lesions: Periorbital IH risking visual axis obstruction and amblyopia; subglottic IH compromising the airway; large segmental facial IH with significant disfigurement risk; ulcerated IH causing pain and secondary infection; hepatic IH associated with high-output cardiac failure.
• Residual post-involution telangiectasia: Persistent surface blood vessels after natural IH involution in older children or adults, treated with pulsed dye laser (PDL) at 585/595 nm.
• Rosacea subtype I (erythematotelangiectatic): Facial erythema, flushing, and visible telangiectasia. Addressed by topical brimonidine gel for transient erythema and by IPL/PDL for established telangiectasia.
• Rosacea subtype II (papulopustular): Inflammatory papules and pustules resembling acne but distinguished by absence of comedones. Treated with topical metronidazole, azelaic acid, or ivermectin 1%, with or without oral doxycycline 40 mg MR.
• Rosacea subtype III (phymatous): Rhinophyma — fibrous and sebaceous hypertrophy of the nose — and phymatous change of the chin, forehead, or ears. Treated with CO2 ablative laser or electrocautery.
• Rosacea subtype IV (ocular): Blepharitis and conjunctivitis; managed by ophthalmology with lid hygiene; systemic doxycycline addresses both cutaneous and ocular rosacea.
• Acne vulgaris — procedural targets: Persistent comedones refractory to topical retinoids; inflammatory nodules and cysts requiring rapid resolution; post-inflammatory hyperpigmentation and early atrophic scarring.

Propranolol for infantile haemangioma: All infants aged >5 weeks corrected gestational age with high-risk IH are candidates. Absolute contraindications include: bronchial asthma or reactive airway disease; bradycardia or second/third-degree heart block; cardiogenic shock; and hypoglycaemia risk in poorly feeding neonates. ECG and paediatric cardiac assessment are required before initiation. Premature infants require additional monitoring. Baseline weight, heart rate, and blood pressure are recorded; monitoring occurs 1–2 hours post first dose and after each dose escalation.

Laser and light therapy (PDL and IPL): Most suitable for Fitzpatrick skin types I–IV. Patients with darker skin types (IV–VI) face higher risk of post-inflammatory pigmentation with high-fluence PDL and IPL; treatment settings must be adjusted accordingly. Relative contraindications to laser include: active skin infection or herpes simplex at the treatment site; pregnancy (device-specific, assess case by case); photosensitising medications at standard doses (e.g., full-dose doxycycline, not the 40 mg MR subantimicrobial formulation); isotretinoin use within the preceding 6 months (impaired wound healing).

Acne procedures: Comedone extraction and intralesional triamcinolone are suitable for adults and older adolescents with stable, localised comedonal or nodular acne confirmed clinically. Chemical peels require Fitzpatrick skin type assessment: superficial peels (salicylic acid 20–30%, glycolic acid 30–50%) are safe across all skin types; medium-depth TCA peels carry substantial dyspigmentation risk in skin types IV–VI and require pre-conditioning and specialist expertise. Pregnancy is a contraindication to retinoid-containing peels and salicylate preparations (systemic absorption risk).

Infantile Haemangioma treatments:

• Oral propranolol (HEMANGIOL 3.75 mg/ml oral solution): Commenced at 1 mg/kg/day in two divided doses, escalated to 3 mg/kg/day over 1 week. Minimum treatment duration is 6 months. Mechanism includes immediate beta-adrenergic vasoconstriction, inhibition of VEGF and bFGF-driven proliferation, and induction of endothelial apoptosis. The IPHES trial (N=456) demonstrated 60.4% complete or near-complete resolution at 24 weeks with 3 mg/kg/day versus 3.6% with placebo.
• Topical timolol maleate 0.5% gel-forming solution: Beta-blocker applied topically twice daily for small, superficial IH; avoids systemic side effects; evidence from multiple cohort studies supports efficacy for thin lesions.
• Pulsed Dye Laser (PDL, 585/595 nm): Targets oxyhaemoglobin selectively; used for superficial proliferating IH and for residual telangiectasia following involution. Typically 4–6 sessions at 6-week intervals required.

Rosacea treatments:

• Topical metronidazole 0.75% or 1% (Rozex, MetroGel): First-line for papulopustular rosacea; applied twice daily; reduces inflammatory lesion count by 50–70% in RCTs versus vehicle.
• Topical azelaic acid 15% gel (Finacea): Alternative first-line; anti-inflammatory and mildly comedolytic; well-tolerated in pregnancy (limited use cases).
• Topical ivermectin 1% cream (Soolantra): Demonstrated superiority over metronidazole 0.75% in a head-to-head RCT (Taieb 2015, Br J Dermatol) at both 16 and 52 weeks; targets Demodex mite co-pathogenesis.
• Oral doxycycline 40 mg modified-release (Oracea/Efracea): Subantimicrobial dose providing anti-inflammatory effect without antibiotic selection pressure; first-line systemic agent per BAD and AAD guidelines for moderate-to-severe papulopustular rosacea.
• Brimonidine 0.5% gel (Mirvaso): Selective alpha-2 adrenergic agonist applied once daily for transient erythema reduction; effect lasts 8–12 hours; does not treat telangiectasia.
• IPL and PDL for telangiectasia: IPL uses 515–1200 nm filtered broadband light; effective for background erythema and diffuse telangiectasia. PDL (585/595 nm) is preferred for discrete vessels. Both require 3–5 sessions at 4–6 week intervals.
• CO2 laser for rhinophyma: Ablates hypertrophied sebaceous and fibrous tissue precisely; performed under topical or local anaesthesia; healing takes 1–2 weeks; highly effective with superior cosmetic results over surgical shave.

Acne removal procedures:

• Comedone extraction: Manual expression using a Schamberg or comedone extractor following gentle skin warming; effective for open (blackheads) and closed (whiteheads) comedones.
• Intralesional triamcinolone acetonide (2.5–5 mg/ml): Injected directly into inflammatory nodules and cysts; rapid resolution within 24–48 hours; prevents scarring from spontaneous rupture.
• Chemical peels: Salicylic acid 20–30% (oil-soluble, comedolytic, suited to oily acne-prone skin); glycolic acid 30–70% (keratolytic, exfoliative); TCA 10–25% for deeper resurfacing of acne scarring.
• Phototherapy: Blue light (415 nm) activates endogenous porphyrins in C. acnes, generating cytotoxic singlet oxygen. PDL and broadband light are used as adjuncts for mild-to-moderate inflammatory acne.

• Propranolol for IH: Dramatically improved outcomes for high-risk haemangiomas; prevents visual complications from periorbital lesions and airway compromise from subglottic lesions; replaces riskier surgical and systemic corticosteroid approaches; safe with appropriate monitoring; avoids the cosmetic and functional sequelae of large involuting untreated haemangiomas.
• PDL/IPL for rosacea telangiectasia: Provides durable reduction of visible blood vessels not achievable with topical therapy alone; outcomes maintained for 12–24 months with appropriate maintenance sessions; minimal downtime compared to surgical approaches.
• Ivermectin 1% cream: Superior sustained efficacy versus metronidazole at 52 weeks; addresses the underlying Demodex mite contribution to rosacea pathophysiology; low irritation profile and good patient tolerability.
• Brimonidine gel: Provides rapid visible reduction of facial redness within 30 minutes of application; useful for patients with important social or professional events; the only licensed topical therapy specifically targeting transient erythema rather than inflammatory lesions.
• CO2 laser for rhinophyma: Precise tissue ablation with immediate visible improvement in nasal contour; superior cosmetic outcome to surgical reshaping in experienced hands; outpatient procedure under local anaesthesia.
• Intralesional triamcinolone for acne: Rapid lesion resolution within 24–48 hours, reducing the risk of permanent scarring from nodule rupture; particularly valuable before high-profile occasions; single injection is usually sufficient per lesion.
• Chemical peels: Address multiple acne lesion types and sequelae simultaneously; improve post-inflammatory hyperpigmentation and superficial scarring alongside active acne; cost-effective and repeatable outpatient procedures.

• Propranolol for IH: Bradycardia, hypotension, bronchospasm, and hypoglycaemia are the primary systemic risks, particularly if feeds are missed or delayed. Sleep disturbance and cold extremities are common minor side effects. Abrupt discontinuation may cause rebound rapid proliferation — gradual tapering over 4 weeks is mandatory at end of treatment.
• PDL for haemangioma and rosacea: Purpura (therapeutic bruising at higher fluences) lasting 7–14 days; transient erythema, oedema, and crusting; dyspigmentation in darker skin types (post-inflammatory hypo- or hyperpigmentation); very rarely scarring if settings are inappropriate or skin inadequately cooled.
• IPL: Similar to PDL; risk of hyperpigmentation is higher in skin types IV–VI; eye protection is mandatory; paradoxical erythema exacerbation occasionally reported in highly sensitive rosacea skin.
• Intralesional triamcinolone for acne: Skin atrophy and hypopigmentation at the injection site occur if the dose is too high (>5 mg/ml) or volume too large; generally reversible over months but may persist. Telangiectasia formation at the injection site with repeated treatment.
• Chemical peels: Erythema and desquamation (expected); post-inflammatory hyperpigmentation (particularly in Fitzpatrick IV–VI); herpes simplex reactivation requiring antiviral prophylaxis for medium and deep peels; scarring from incorrect technique, inadequate skin preparation, or excessively deep penetration.
• CO2 laser for rhinophyma: Oedema and crusting lasting 1–2 weeks; erythema may persist for several weeks; risk of secondary infection; permanent hypopigmentation in darker skin types; ectropion risk near the nasal ala if technique is not precise.
• Brimonidine gel: Rebound erythema (paradoxical worsening when effect wears off, affecting approximately 10–15% of users); occasional paradoxical flushing; not suitable for patients with severe cardiovascular disease or Raynaud's phenomenon.

Propranolol for IH: Monthly clinical review during active treatment to assess haemangioma response, monitor heart rate and blood pressure, and adjust dose for weight gain. After 6–12 months of treatment, gradual dose tapering over 4 weeks is essential to prevent rebound proliferation. PDL follow-up for any residual telangiectasia is arranged at 12–18 months post-involution. Parents are counselled on signs of adverse effects (bradycardia <100 bpm in infants, respiratory distress) requiring emergency review.

Rosacea: Topical treatment response is assessed at 8–12 weeks. Maintenance therapy with lower-frequency topical application is typically required indefinitely given the chronic relapsing nature of rosacea. IPL/PDL outcomes are reviewed at 3 months post-course; maintenance sessions are planned every 12–18 months based on clinical response. Trigger identification and avoidance — UV exposure, alcohol, spicy food, temperature extremes, vigorous exercise — is integral to patient education at follow-up appointments.

Acne procedures: Chemical peel series typically involves 4–6 sessions at 2–4 week intervals, with standardised photography at each visit to objectively document progress. Intralesional triamcinolone patients should be reviewed at 2 weeks to assess for atrophy or hypopigmentation and to evaluate whether additional lesions require treatment. Ongoing pharmacological acne management with topical retinoids, azelaic acid, and/or oral antibiotics should continue concurrently with procedural treatments to address underlying pathophysiology. Transition to isotretinoin should be considered for patients with severe, scarring, or treatment-refractory acne.

• Propranolol (HEMANGIOL): NHS-funded for high-risk IH in the UK via specialist paediatric dermatology or oncology referral. Branded HEMANGIOL solution in private settings: approximately GBP 200–400 for a 6-month course. Generic oral propranolol liquid is substantially cheaper and used in some treatment protocols.
• PDL sessions: USD 300–600 per session in the USA; 4–6 sessions typically required for rosacea telangiectasia; total course USD 1,200–3,600. Available at NHS dermatology laser units (funded referrals for high-risk IH) and private aesthetic medicine clinics.
• IPL: USD 150–400 per session in the USA; GBP 100–300 in the UK privately; multiple sessions required. Available at a wider range of aesthetic clinics than PDL.
• CO2 laser for rhinophyma: USD 1,000–3,500 per procedure in the USA; GBP 800–2,500 privately in the UK. Some cases qualify for NHS treatment if functional nasal obstruction is documented alongside cosmetic deformity.
• Chemical peels: USD 75–300 per session depending on depth and agent (superficial to medium); a standard series of 4–6 sessions total: USD 400–1,800. Widely available at dermatology clinics and medically supervised aesthetic facilities.
• Intralesional triamcinolone: USD 50–150 per injection visit in the USA; available through NHS dermatology referral at no direct patient cost in the UK for medically indicated acne treatment.
• Medical tourism: All laser and procedural dermatology treatments are available in India, Thailand, and Turkey at 40–70% lower cost than UK/USA private pricing, at specialist dermatology and aesthetic medicine centres in major cities.

• Haemangioma alternatives: Watchful waiting with regular review for small, non-high-risk IH (many involute without treatment by age 7). Systemic corticosteroids (prednisolone 2–3 mg/kg/day) remain second-line when propranolol is contraindicated. Surgical excision is reserved for pedunculated residual IH post-involution or following failed medical therapy. Vincristine is reserved for life-threatening, unresponsive lesions.
• Rosacea alternatives — topical: Topical sulfacetamide-sulfur preparations (older option with antimicrobial and anti-seborrhoeic properties); oxymetazoline 1% cream (Rhofade) for persistent erythema (alpha-1 agonist); topical retinoids (off-label, limited evidence).
• Rosacea alternatives — systemic: Low-dose isotretinoin (0.1–0.3 mg/kg/day, off-label) for severe, refractory rosacea particularly phymatous change; tetracycline or lymecycline as alternatives to doxycycline where 40 mg MR is unavailable.
• Acne alternatives — systemic: Oral doxycycline or lymecycline for inflammatory acne; combined oral contraceptive pill (co-cyprindiol) for hormonal acne in females; spironolactone 50–150 mg/day (off-label in UK but NICE-approved in USA via FDA) for androgen-driven acne in females; oral isotretinoin (standard 0.5–1.0 mg/kg/day) for severe nodulocystic or scarring acne — the most effective acne treatment available.
• Laser alternatives for telangiectasia: Vascular sclerotherapy (more commonly for leg telangiectasia); electrocautery fine-needle treatment for isolated facial telangiectasia; long-pulsed Nd:YAG laser as an alternative to PDL for deeper or resistant vessels.